Azivoc-500 Tablet

Diagnostics Innovation Biotech Environment Testing Research Diagnostics Innovation Biotech
Diagnostics Innovation Biotech Environment Testing Research Diagnostics Innovation Biotech
Pantalis 40 Injection VOCLAV 625 Rbvoc-DSR Rabeprazole Listuss - Syrup Vocalis SP Pantalis-D Listus-AM DIVOC CEFOTEM-1.5 INJ CEFTRALIS INJ
VOCLAV 625 Rbvoc-DSR Rabeprazole Listuss - Syrup Vocalis SP Pantalis-D Listus-AM DIVOC VOCLAV 625 Azivoc-500 tab Rbvoc-DSR Rabeprazole

Explore Our Prodcuts

Azivoc-500 Tablet delivers broad-spectrum antibacterial protection for patients suffering from bacterial infections of the respiratory tract, skin, soft tissues, and genitourinary system. Formulated with Azithromycin 500 mg, a macrolide antibiotic, it works by inhibiting bacterial protein synthesis, ensuring rapid eradication of infection and faster recovery. With its high tissue penetration and prolonged half-life, Azivoc-500 offers the advantage of once-daily dosing, enhancing patient compliance and therapeutic outcomes.

Azivoc-500 is highly effective in the treatment of community-acquired pneumonia, acute bacterial sinusitis, pharyngitis, tonsillitis, skin infections, urethritis, and cervicitis. Its proven efficacy extends to both Gram-positive and Gram-negative pathogens, as well as atypical organisms, making it a versatile solution in modern antimicrobial therapy.

Backed by clinical evidence, Azivoc-500 demonstrates excellent cure rates, with rapid symptomatic relief in respiratory infections and reduced recurrence rates in chronic cases. Its convenient oral formulation ensures reliable absorption and bioavailability, making it ideal for outpatient as well as hospital-based care.

Research & Clinical Data for Azivoc-500

Indications Supported by Evidence

  • Respiratory Tract Infections: Significant reduction in fever, cough, and sputum production within 48–72 hours.
  • Skin & Soft Tissue Infections: Proven effectiveness in cellulitis, folliculitis, and erysipelas with high patient tolerance.
  • ENT Infections: Demonstrated cure rates in acute otitis media, bacterial sinusitis, and pharyngitis.
  • Genitourinary Infections: Strong clinical response in chlamydial and gonococcal urethritis/cervicitis.

Azivoc-500 is a trusted, safe, and clinically validated antibiotic that restores health and ensures superior patient outcomes by combining efficacy, convenience, and reliability.